Clinical Research Directory

Inclusion Criteria: * Patients with multiple myeloma who previously received GC012F Injection infusion in an investigator-initiated trial; * Patients who have completed the safety and efficacy follow-up of the main study or withdrawn early; * Patients who agree to sign the informed consent form and are willing and able to comply with the visits, laboratory tests, and other protocol requirements specified in the study visit schedule; Exclusion Criteria: * Patients with multiple myeloma who participated in the main study but withdrew early without receiving GC012F Injection; * Patients who refuse to undergo long-term follow-up after GC012F Injection treatment;